By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Centrexion 

509 S Exeter Street #202,

Baltimore  Maryland  21202  U.S.A.
Phone: 410-522-8701 Fax: n/a


SEARCH JOBS

Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.

YEAR FOUNDED:

December 2013

LEADERSHIP:

CEO: Jeffrey B. Kindler

Chief Veterinary Officer: Peter Hanson, DVM, Ph.D.

Chief Business Officer: Kerrie Brady, BPharm, MS, MBA

CFO: Gregg Beloff, J.D., MBA

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@centrexion.com
Ownership: Private

Web Site: Centrexion
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Centrexion Provides Updates And Advancements For Pipeline Of Chronic Pain Treatments 7/18/2017 6:40:49 AM
Centrexion Names Shawn Tomasello To Its Board Of Directors 6/27/2017 7:25:29 AM
Centrexion Announces New 6-Month Data Demonstrating Significant And Durable Pain Relief With CNTX-4975 For Treatment Of Moderate To Severe Knee Osteoarthritis Pain 6/14/2017 7:40:52 AM
Centrexion Announces Oral Presentation Of Six Month Efficacy Data On Cntx-4975 For The Treatment Of Chronic Pain Associated With Knee Osteoarthritis At The Annual European Congress Of Rheumatology (Eular 2017) 6/7/2017 8:09:54 AM
Centrexion To Present Data On CNTX-4975 For The Treatment Of Chronic Pain Associated With Knee Osteoarthritis At European Federation Of National Associations Of Orthopaedics And Traumatology’s 2017 Annual Congress 5/25/2017 6:57:16 AM
Centrexion To Present Data On CNTX-4975 For The Treatment Of Chronic Pain Associated With Morton’s Neuroma And Knee Osteoarthritis At American Pain Society 2017 Annual Scientific Meeting 5/10/2017 7:56:24 AM
Centrexion To Present Data On CNTX-4975 From The Treatment Of Knee Osteoarthritis Pain At IX SIMPAR-ISURA 3/23/2017 8:19:11 AM
Centrexion To Present Late-Breaking Poster At The 33rd Annual American Academy Of Pain Medicine Meeting 3/16/2017 7:27:28 AM
Centrexion Announces Highly Statistically Significant Topline Results From Phase 2b Study Of CNTX-4975 In Patients With Knee Osteoarthritis Pain 12/13/2016 11:14:23 AM
Centrexion Touts Success of Phase IIb Study for Knee Osteoarthritis Pain 12/13/2016 5:48:45 AM
12
//-->